Name | Detomidine hydrochloride |
Synonyms | API017 DTMT.HCl DoMosedan MPV 253AII DorMosedan Detomidine hydrochloride DetoMidine hydrochloride (DorMosedan) 5-(2,3-Dimethylbenzyl)imidazole Hydrochloride 5-[(2,3-DiMethylphenyl)Methyl]-1H-iMidazole Hydrochloride 4-[(2,3-Dimethylphenyl)methyl]-1H-imidazole monohydrochloride |
CAS | 90038-01-0 |
InChI | InChI=1/C12H14N2.ClH/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12;/h3-5,7-8H,6H2,1-2H3,(H,13,14);1H |
InChIKey | OIWRDXKNDCJZSM-UHFFFAOYSA-N |
Molecular Formula | C12H15ClN2 |
Molar Mass | 222.7139 |
Melting Point | 160°C |
Boling Point | 386.5°C at 760 mmHg |
Flash Point | 200.6°C |
Solubility | Soluble in water, methanol, and DMSO. |
Vapor Presure | 7.83E-06mmHg at 25°C |
Appearance | neat |
Color | White to Off-White |
Storage Condition | Sealed in dry,Room Temperature |
Use | An α2-adrenergic agonist. |
In vitro study | Currently, detomidine is only licenced for use in horses. Detomidine is a sedative with analgesic properties. α2-adrenergic agonists produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors, thus inducing a negative feedback response, reducing production of excitatory neurotransmitters. Due to inhibition of the sympathetic nervous system, detomidine also has cardiac and respiratory effects and an antidiuretic action. |
UN IDs | UN 2811 6.1 / PGIII |
RTECS | NI5160000 |